• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552

Professional Introduction to Compound with CAS No. 113511-45-8 and Product Name: 3-amino-3-(1,3-dioxaindan-5-yl)propan-1-ol

The compound with the CAS number 113511-45-8 and the product name 3-amino-3-(1,3-dioxaindan-5-yl)propan-1-ol represents a significant advancement in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique structural framework, has garnered considerable attention due to its potential applications in drug development and therapeutic interventions. The molecular structure of 3-amino-3-(1,3-dioxaindan-5-yl)propan-1-ol incorporates a dioxaindan moiety, which is a heterocyclic compound known for its stability and versatility in chemical reactions. This feature makes it an attractive candidate for further exploration in medicinal chemistry.

In recent years, there has been a growing interest in the development of novel compounds that can modulate biological pathways associated with various diseases. The dioxaindan scaffold, present in 3-amino-3-(1,3-dioxaindan-5-yl)propan-1-ol, has been extensively studied for its ability to interact with biological targets such as enzymes and receptors. This interaction is crucial for the development of drugs that can selectively target specific disease mechanisms. The presence of an amino group in the molecular structure further enhances the compound's potential as a pharmacophore, allowing for modifications that can improve solubility, bioavailability, and overall efficacy.

One of the most compelling aspects of 3-amino-3-(1,3-dioxaindan-5-yl)propan-1-ol is its potential role in addressing unmet medical needs. Current research indicates that this compound may exhibit properties that are beneficial in the treatment of neurological disorders, inflammatory conditions, and even certain types of cancer. The dioxaindan core is known to exhibit significant bioactivity, and when combined with other functional groups such as amines, it can lead to compounds with enhanced therapeutic potential. This has prompted researchers to explore synthetic pathways that can optimize the yield and purity of 3-amino-3-(1,3-dioxaindan-5-yl)propan-1-ol, ensuring that it meets the stringent requirements for clinical trials.

The synthesis of 3-amino-3-(1,3-dioxaindan-5-yl)propan-1-ol involves a series of carefully orchestrated chemical reactions that highlight the expertise required in organic synthesis. The process typically begins with the preparation of the dioxaindan ring system, which is then functionalized to introduce the amino group at the appropriate position. Advanced techniques such as catalytic hydrogenation and nucleophilic substitution are often employed to achieve high yields and minimize side reactions. These synthetic strategies are critical for producing compounds that are both pure and scalable for industrial applications.

In terms of biological activity, preliminary studies on 3-amino-3-(1,3-dioxaindan-5-yl)propan-1-ol have shown promising results. Researchers have observed that this compound can interact with various enzymes and receptors in vitro, suggesting potential therapeutic effects. For instance, it may inhibit enzymes involved in inflammation or block receptors that are overactive in certain neurological conditions. These findings have spurred further investigation into the compound's mechanism of action and its potential as a lead molecule for drug development.

The pharmaceutical industry is increasingly recognizing the value of innovative compounds like 3-amino-3-(1,3-dioxaindan-5-yi)propanol. Companies are investing heavily in research and development to identify new molecular entities that can address complex diseases more effectively than existing treatments. The unique properties of this compound make it a compelling candidate for further exploration, particularly as part of combination therapies or novel drug regimens. The ability to fine-tune its structure through synthetic chemistry offers a pathway to develop multiple derivatives with tailored pharmacological profiles.

As our understanding of biological systems continues to evolve, so does our ability to design compounds that can interact with them in meaningful ways. The case of CAS No. 113511458 and product name: 33amino33(13dioxaind an5y l)propa n11ol underscores this point perfectly. By leveraging advances in synthetic chemistry and computational biology, researchers are paving the way for new treatments that could revolutionize healthcare. The continued study of this compound promises to yield insights that could have far-reaching implications not only for drug development but also for our fundamental understanding of disease mechanisms.

In conclusion,33amino33(13diox ain dan5y l)propa n11ol represents a significant step forward in the quest for novel therapeutic agents. Its unique structural features and promising biological activity make it a valuable asset in ongoing research efforts aimed at addressing some of the most challenging medical conditions today. As scientists delve deeper into its properties and potential applications,CAS No 11351 1458 will undoubtedly play a crucial role in shaping the future of pharmaceutical innovation.

• 5471-42-1( )
• 6273-66-1(3-(1,3-benzodioxol-5-yl)-1-phenylpropan-1-amine;hydrochloride)
• 197508-49-9((R)-[3',4'-(Methylenedioxy)phenyl]-1-butylamine hydrochloride)
• 127292-42-6(1,3-Benzodioxole-5-methanamine,a-ethyl-)
• 886366-32-1((R)-3-(3-Hydroxy-4-methoxyphenyl)-β-alaninol)
• 6278-55-3(1-(1,3-benzodioxol-5-yl)-2-phenylethanamine;hydrochloride)
• 136765-42-9((+/-)-3,4-methylenedioxyamphetamine-d5)
• 181481-62-9((R)-1-(Benzo[d][1,3]dioxol-5-yl)butan-1-amine)
• 886366-29-6(4-(1-Amino-3-hydroxypropyl)-2-methoxyphenol)
• 113511-49-2(3-Amino-3-benzo1,3dioxol-5-yl-propan-1-ol Hydrochloride)